[Correspondence] Whose vitiligo goes untreated?

The Lancet Editorial1 on skin diseases rightly argues that vitiligo trials such as Viti-Up, in which more than 70% of participants were White, should enrol patients who reflect the population affected and measure what lies beyond the visible: stigma, comorbidity, and quality of life. The same oversight, however, occurs throughout observational literature, shaping how we judge health care.